COMMUNIQUÉS West-GlobeNewswire
-
Northwestern Medicine Announces the Robert Havey, MD, Institute for Primary Care
20/07/2026 -
Route 92 Medical Celebrates the 200th Patent for its Neurovascular Intervention Portfolio
20/07/2026 -
New resources on the way for BC farms under pressure from pests and disease
20/07/2026 -
Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction
20/07/2026 -
Novo Nordisk A/S - share repurchase programme
20/07/2026 -
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
20/07/2026 -
CDT Highlights Sarborg's Patent Filing Extending Quantum-Enabled PRISM Platform to Sugarcane
20/07/2026 -
Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress
20/07/2026 -
Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026
20/07/2026 -
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
20/07/2026 -
University of Szeged Pioneers First Robotic Cardiology Program in Hungary
20/07/2026 -
DLH to Announce Fiscal 2026 Third Quarter Financial Results
20/07/2026 -
Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston
20/07/2026 -
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
20/07/2026 -
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
20/07/2026 -
Noom Launches 'Lose for Keeps' with Rebel Wilson, a New Campaign Making the Case That GLP-1 Medication and Healthy Habits Work Better Together
20/07/2026 -
Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market
20/07/2026 -
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
20/07/2026 -
Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion
20/07/2026
Pages